SCHEMBL189828

SCHEMBL189828

NC(=O)OCc1cc(-c2ccc(OCc3ccc(Cl)cc3)cc2)no1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.61
MAPT P10636 4/20 0.61
SMN1; SMN2 Q16637 4/20 0.60
RAB9A P51151 4/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
SMPD1 P17405 2/20 0.51
NOTUM Q6P988 2/20 0.49
TDP1 Q9NUW8 3/20 0.47
NPC1 O15118 3/20 0.47
POLB P06746 2/20 0.47
JAK2 O60674 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
ALOX5 P09917 1/20 0.46
ALOX5AP P20292 1/20 0.46
NR4A2 P43354 1/20 0.45
LMNA P02545 1/20 0.45
DHFR P00374 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190018 0.89 MAPT (0.50) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL190288 0.89 PARP10 (0.56) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189490 0.89 RAB9A (0.60) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189525 0.89 RAB9A (0.60) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189840 0.89 RAB9A (0.59) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189690 0.88 RAB9A (0.54) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189148 0.88 L3MBTL1 (0.49) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189528 0.88 SMN1; SMN2 (0.48) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189195 0.87 RAB9A (0.46) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1
SCHEMBL189596 0.87 RAB9A (0.49) L3MBTL1MAPTSMN1; SMN2RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US claimed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP claimed
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO LTD (KR) 2014-11-27 US claimed
US-8841335-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-23 US claimed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US claimed
EP-2566475-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK Biopharmaceuticals Co., Ltd. (KR) 2013-03-13 EP claimed
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-02-21 US claimed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP claimed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US claimed
WO-2011139079-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-11-10 WO claimed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO claimed
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US disclosed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO LTD (KR) 2014-11-27 US disclosed
US-8841335-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-23 US disclosed
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-02-21 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2011139079-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-11-10 WO disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 L3MBTL1 4729/4885MAPT 313/4885SMN1; SMN2 268/4885
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION BAX, NLN, CASP3 L3MBTL1 2556/4885MAPT 29/4885SMN1; SMN2 15/4885
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION BAX, NLN, CASP3 L3MBTL1 2556/4885MAPT 29/4885SMN1; SMN2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.